H.C. Wainwright analyst Michael King maintained a Buy rating on Exelixis (NASDAQ:EXEL) on Friday, setting a price target of $47, which is approximately 112.38% above the present share price of $22.13.
King expects Exelixis to post earnings per share (EPS) of $0.01 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Exelixis, with an average price target of $32.29.
The analysts price targets range from a high of $47 to a low of $23.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $270.23 million and a net profit of -$4.61 million. The company's market cap is $6.94 billion.
According to TipRanks.com, H.C. Wainwright analyst Michael King is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.8% and a 56.82% success rate.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.